Mineralys Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
MLYS$15.52-1.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2023 and 2022
Balance Sheets
(in thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $49,304 | $87,701 |
| Investments | 187,263 | 22,409 |
| Prepaid and other current assets | 12,536 | 2,701 |
| Total current assets | 249,103 | 112,811 |
| Investments, noncurrent | 2,482 | — |
| Other assets | 51 | 1,631 |
| Total assets | $251,636 | $114,442 |
| Liabilities, convertible preferred stock, and stockholders’ equity (deficit) | ||
| Current liabilities: | ||
| Accounts payable | $601 | $1,907 |
| Accrued liabilities | 9,881 | 6,160 |
| Total current liabilities | 10,482 | 8,067 |
| Commitments and contingencies (Note 4) | ||
| Series A convertible preferred stock, $0.0001 par value, 0 and 86,332,216 shares authorized and 0 and 86,332,216 shares issued and outstanding as of December 31, 2023 and 2022, respectively, $0 and $41,180 aggregate liquidation preference as of December 31, 2023 and 2022, respectively | — | 40,987 |
| Series B convertible preferred stock, $0.0001 par value, 0 and 136,510,868 shares authorized and 0 and 136,510,868 shares issued and outstanding as of December 31, 2023 and 2022, respectively, $0 and $118,000 aggregate liquidation preference as of December 31, 2023 and 2022, respectively | — | 117,657 |
| Stockholders’ equity (deficit): | ||
| Common stock, $0.0001 par value, 500,000,000 and 319,000,000 shares authorized and 41,133,916 and 6,419,238 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 4 | 1 |
| Additional paid-in capital | 365,858 | 540 |
| Accumulated deficit | (124,708) | (52,810) |
| Total stockholders’ equity (deficit) | 241,154 | (52,269) |
| Total liabilities, convertible preferred stock, and stockholders’ equity (deficit) | $251,636 | $114,442 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.